Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Lemons for Obesity” Or Sour Grapes? A Key Dissent on Qnexa, With a Twist of Avandia

This article was originally published in RPM Report

Executive Summary

NIH Cardiologist Michael Lauer takes a page out of the Cleveland Clinic playbook and rips an advisory committee for recommending approval of Vivus’ Qnexa for weight loss without demanding a pre-market outcomes study. But this is no Avandia: Cleveland Clinic cardiologist Michael Lincoff is on the other side of this debate.

You may also be interested in...

“Feasibility” Counts at FDA: Different Approach in Antibiotics

Venture capitalists and other investors in drug development often howl about FDA policy changes that they view as crippling innovation in certain classes. They may not think FDA listens, but clearly the agency does. FDA just doesn’t always agree.

The Inevitable Outcome: Diabetes Safety Model Expands to Weight Loss…and Beyond?

The cardiovascular outcomes standard used for diabetes drugs since 2008 is moving to weight loss. That is important in itself, but also for what it says about the lessons FDA has taken from the diabetes experience—and what it might mean about regulatory expectations for other chronic drug classes in the future.

Setting the Stage: Qnexa and the Power of REMS

Vivus’ second trip to an advisory panel was a much happier one, with the company’s weight loss therapy garnering an overwhelming “yes” vote on approvability. The key change? A Risk Evaluation & Mitigation Strategy that will be precedent setting if approved—and that demonstrates the power of REMS even if FDA moves in a different direction with this application.

Related Content


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts